Site Editor

Joyce F. Liu, MD, MPH

Advertisement

Advertisement

Medical Literature

Relacorilant Added to Nab-Paclitaxel Benefits Patients With Platinum-Resistant Ovarian Cancer

News

ASCO 2025: A Noninvasive Diagnostic Tool for Ovarian Cancer

News

AACR 2025: Are OTTA-SPOT Scores an Accurate Prognostic Tool for Black Patients With Ovarian Cancer?

Medical Literature

Quantifying the Global Socioeconomic Burden of Ovarian Cancer

News

Translational Data From Early-Phase Trial of Novel Immunotherapy for Advanced Ovarian Cancer

News

Australian Clinical Trial to Assess Next-Generation Screening Test for Ovarian Cancer

Medical Literature

Do Ovarian Tumor Cells Sabotage Nearby Cells Using Long Noncoding RNA?

Videos

Daniela E. Matei, MD on Biology-Driven Therapy for Ovarian Cancer

Videos

Lainie P. Martin, MD, Antibody-Drug Conjugates and Ovarian Cancer

Advertisement

JNCCN Spotlights

Olaparib (Lynparza)

Bevacizumab (Avastin®)

(UPDATE) Niraparib (Zejula)

Trametinib (Mekinist®)—Low-Grade Serous Ovarian Carcinoma

View More

More

News

FOLR1 as a Therapeutic Target in Low-Grade Serous Ovarian Carcinoma

Genomic Instability: Linked to Survival Outcomes in BRCA1/2 Wild-Type Ovarian Cancer

SOLO3 Survival Update: Olaparib vs Nonplatinum Chemotherapy for Relapsed Ovarian Cancer

AACR 2025: Are OTTA-SPOT Scores an Accurate Prognostic Tool for Black Patients With Ovarian Cancer?

Repeated Laparoscopic Extensive Surgery for Rare Ovarian Cancer: Case Report

ASCO 2025: A Noninvasive Diagnostic Tool for Ovarian Cancer

RMAT Designation Granted by the FDA for Gemogenovatucel-T in Advanced Ovarian Cancer

Can Metabolic Imaging Discern Subtypes in High-Grade Serous Ovarian Cancer?

View More

Advertisement

Published

Medical Literature

WEE1 Inhibitor Adavosertib Plus Gemcitabine in High-Grade Serous Ovarian Cancer

Does IgA Affect Antitumor Activity of Immune Cells in Ovarian Cancer?

Individualized Niraparib Dosing for Platinum-Sensitive Recurrent Ovarian Cancer

Chemotherapy Before or After Surgery in Advanced Ovarian Cancer: Comparing Outcomes

View More

Ongoing

CE Activities

Optimal integration of pembrolizumab into the care of patients with metastatic MSI-high/dMMR gynecologic cancers

Research experience with and ongoing evaluation of anti-PD-1/PD-L1 antibodies in combination with chemotherapy or targeted therapy for advanced ovarian cancer

Addressing Persistent Challenges in Treatment and Management of Low-Grade Serous Ovarian Carcinoma to Amplify the Latest Evidence in Emerging Therapies

Evolution of the Care of Patients With Advanced Ovarian Cancer

View More

Available

Clinical Trials

City of Hope

Fox Chase Cancer Center

Fred Hutchinson Cancer Research Center

Helen Diller Family Comprehensive Cancer Center

View More

Resources

For Your Patients

CancerCare

Foundation for Women's Cancer

American Cancer Society

Rivkin Center for Ovarian Cancer

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2025 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.